How many insider trades does FilingIQ track for DWTX?

FilingIQ tracks 12 Form 4 insider transactions for DWTX (Dogwood Therapeutics, Inc.), covering filings from Nov 21, 2025 onwards. 4 of those were filed in the last 90 days.

Are DWTX insiders net buyers or net sellers?

Across the full Form 4 history for DWTX, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does DWTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is DWTX in?

Dogwood Therapeutics, Inc. (DWTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $92.72M.

DWTX insider trading

NasdaqCM Healthcare

Dogwood Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 0%

Market cap

$92.72M

About Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.

Company website: dwtx.com

DWTX insider activity at a glance

FilingIQ has scored 12 insider transactions for DWTX since Nov 21, 2025. The most recent filing in our index is dated Mar 5, 2026.

Across the full history, 0 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live DWTX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for DWTX?: FilingIQ tracks 12 Form 4 insider transactions for DWTX (Dogwood Therapeutics, Inc.), covering filings from Nov 21, 2025 onwards. 4 of those were filed in the last 90 days.
Are DWTX insiders net buyers or net sellers?: Across the full Form 4 history for DWTX, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does DWTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is DWTX in?: Dogwood Therapeutics, Inc. (DWTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $92.72M.

Methodology & sources

Every DWTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.